GlassScriptPhysician profile
Rajat Narang
NPI 1225268972
$16,807.86
in general payments reported to CMS, 2019-2025
44 companies · $2,621 in 2025
The $2,621 reported for 2025 was more than what 81% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,693 · 2020: $242 · 2021: $1,892 · 2022: $2,052 · 2023: $5,906 · 2024: $2,402 · 2025: $2,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,040 · Education: $3,122 · Travel and Lodging: $767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,040.44 |
| Education | $3,122.11 |
| Travel and Lodging | $766.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,072.80 | 2023-2025 | Ion, Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $2,227.14 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,452.89 | 2019-2025 | Tezspire, Fasenra, Breztri |
| US Endoscopy | $1,302.66 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,005.86 | 2019-2025 | Ofev, Stiolto Respimat |
| Genzyme Corporation | $569.86 | 2021-2025 | |
| Grifols USA, LLC | $468.49 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $464.09 | 2022-2025 | Glassia |
| Regeneron Healthcare Solutions, INC. | $401.81 | 2019-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $394.92 | 2022-2025 | Acthar |
| Insmed, INC. | $377.10 | 2022-2025 | Arikayce, Brinsupri |
| Sunovion Pharmaceuticals INC. | $343.12 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $288.58 | 2019-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $284.87 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Amgen INC. | $269.76 | 2022-2025 | Tezspire |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $265.85 | 2023-2024 | Veklury |
| Steris Corporation | $246.84 | 2021 | |
| Becton, Dickinson and Company | $235.00 | 2022 | |
| Ethicon INC. | $215.77 | 2021-2022 | |
| Mylan Specialty L.P. | $195.67 | 2019-2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $172.35 | 2022-2024 | Opdivo |
| Merck Sharp & Dohme LLC | $161.69 | 2022-2025 | Zerbaxa, Dificid, Recarbrio |
| Pfizer INC. | $150.69 | 2019-2025 | |
| Pulmonx Corporation | $144.74 | 2023 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Philips North America LLC | $138.27 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Abbvie INC. | $106.03 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Genentech USA, INC. | $95.88 | 2019-2020 | |
| Verona Pharma, INC. | $90.61 | 2025 | Ohtuvayre |
| Inogen, INC. | $82.28 | 2023-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Novartis Pharmaceuticals Corporation | $80.20 | 2019-2024 | |
| United Therapeutics Corporation | $70.65 | 2024 | Tyvaso |
| Shire North American Group INC | $54.36 | 2019 | |
| Viatris Specialty LLC | $51.66 | 2025 | Yupelri |
| Tetraphase Pharmaceuticals, INC. | $41.03 | 2019 | |
| Baxter Healthcare | $35.05 | 2025 | Hillrom - Monarch Airway Clearance System |
| Electromed, INC. | $28.06 | 2025 | Smartvest |
| Csl Behring | $23.42 | 2025 | Hizentra |
| Mallinckrodt Enterprises LLC | $21.06 | 2019 | |
| Circassia INC. | $17.14 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.64 | 2019 | |
| Chiesi USA, INC. | $15.49 | 2024 | Cleviprex |
| Covis Pharma Gmbh | $15.09 | 2022 | |
| Resmed Corp | $12.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajat Narang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.